Skip to Main Content

Cognito Therapeutics has raised $50 million in funding as it seeks to advance treatments for an elusive target: cognitive decline.

Cognito, based in Cambridge, Mass., is developing a headset that feeds a patient light and sound to drive changes in the brains of people with Alzheimer’s disease and other neurological conditions. Cognito will use the new funding from Menlo Park-based FoundersX to complete clinical trials it can submit to the Food and Drug Administration for approval. And with its new Silicon Valley connections comes a techy confidence that the company is sitting on a potential gold mine of data that could lead to a better understanding of the brain and how to treat the diseases that damage it.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment